sources · an illustration

← Source Logic

An illustration · invented records · the research is real and cited

Diagnosis binder

❯

❯

16 items under this folder.

Andre F 2019 — Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Andre F 2022 — Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Bear HD 2017 — Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Freeman JQ 2025 — Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial
Kalinsky K 2021 — 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky K 2026 — Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)
Kang IM 2026 — Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial
Paik S 2004 — A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
Registered clinical trials, as of September 8, 2026
Sgroi DC 2013 — Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Sparano JA 2015 — Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano JA 2018 — Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano JA 2019 — Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Sparano JA 2020 — Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial
Tappenden P 2025 — Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation
Yang SX 2024 — 21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial